Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Non-Current Liabilities: 2010-2022

Historic Total Non-Current Liabilities for China Pharma Holdings (CPHI) over the last 8 years, with Dec 2022 value amounting to $11.1 million.

  • China Pharma Holdings' Total Non-Current Liabilities was N/A to $10.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $10.5 million, marking a year-over-year change of. This contributed to the annual value of $11.1 million for FY2022, which is 24.71% down from last year.
  • China Pharma Holdings' Total Non-Current Liabilities amounted to $11.1 million in FY2022, which was down 24.71% from $14.7 million recorded in FY2021.
  • Over the past 5 years, China Pharma Holdings' Total Non-Current Liabilities peaked at $14.7 million during FY2021, and registered a low of $10.4 million during FY2020.
  • For the 3-year period, China Pharma Holdings' Total Non-Current Liabilities averaged around $12.1 million, with its median value being $11.1 million (2022).
  • Per our database at Business Quant, China Pharma Holdings' Total Non-Current Liabilities spiked by 42.28% in 2021 and then dropped by 24.71% in 2022.
  • China Pharma Holdings' Total Non-Current Liabilities (Yearly) stood at $13.0 million in 2018, then decreased by 18.47% to $10.6 million in 2019, then declined by 2.18% to $10.4 million in 2020, then skyrocketed by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022.